HiTT develops projects for top pharma companies, start-ups, government agencies and consultancy firms in the health industry.
Fundations and public institutions
Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures.
Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.
On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”